Abstract:The majority of human breast cancers are dependent on hormone stimulated estrogen receptor alpha (ER) and are sensitive to its inhibition. Treatment resistance arises in most advanced cancers due to genetic alterations that promote ligand independent activation of ER itself or ER target genes. Whereas re-targeting of the ER ligand binding domain (LBD) with newer ER antagonists can work in some cases, these drugs are largely ineffective in many genetic backgrounds including ER fusions that lose the LBD or in cancers that hyperactivate ER targets. By identifying the mechanism of ER translation, we herein present an alternative strategy to target ER and difficult to treat ER variants. We find that ER translation is cap independent and mTOR inhibitor insensitive, but dependent on 5'UTR elements and sensitive to pharmacologic inhibition of the translation initiation factor eIF4A, an mRNA helicase. EIF4A inhibition rapidly reduces expression of ER and short lived targets of ER such as cyclin D1 and other components of the cyclin D CDK complex in breast cancer cells. These effects translate into suppression of growth of a variety of ligand independent breast cancer models including those driven by ER fusion proteins that lack the ligand binding site. The efficacy of eIF4A inhibition is enhanced when it is combined with fulvestrant, an ER degrader. Concomitant inhibition of ER synthesis and induction of its degradation causes synergistic and durable inhibition of ER expression and tumor growth. The clinical importance of these findings is confirmed by results of an early clinical trial ( ) of the selective eIF4A inhibitor zotatifin in patients with estrogen receptor positive metastatic breast cancer. Multiple clinical responses have been observed on combination therapy including durable regressions. These data suggest that eIF4A inhibition could be a useful new strategy for treating advanced ER+ breast cancer.

Small-Molecule Inhibitors Targeting Eif4a in Leukemia

Regulation of Eukaryotic Translation Initiation Factor 4E as a Potential Anticancer Strategy

Eukaryotic translation initiation factor 4A1 in the pathogenesis and treatment of cancers

Small-molecule induction of phospho-eIF4E sumoylation and degradation via targeting its phosphorylated serine 209 residue.

Expression and Functional Roles of Eukaryotic Initiation Factor 4A Family Proteins in Human Cancers

Phospho-eIF4E: a New Target for Acute Myeloid Leukemia.

Elevated Nuclear Phospho-Eif4e Body Levels Are Associated with Tumor Progression and Poor Prognosis for Acute Myeloid Leukemia

Targeting Translation: Eif4e As an Emerging Anticancer Drug Target.

Targeting of phospho-eIF4E by homoharringtonine eradicates a distinct subset of human acute myeloid leukemia

Targeting EIF4F complex in non-small cell lung cancer cells.

Translational Regulator Eif2α in Tumor

Eukaryotic Translation Initiation Factors and Tumor

Design, Synthesis and Biological Evaluation of Bromophenol-Thiazolylhydrazone Hybrids Inhibiting the Interaction of Translation Initiation Factors Eif4e/eif4g As Multifunctional Agents for Cancer Treatment.

The eIF4E2-Directed Hypoxic Cap-Dependent Translation Machinery Reveals Novel Therapeutic Potential for Cancer Treatment

eIF3a: A new anticancer drug target in the eIF family.

[Role of Eukaryotic Translation Initiation Factor 4G in Tumor].

eIF4A controls translation of estrogen receptor alpha and is a therapeutic target in advanced breast cancer

The eukaryotic translation initiation factor eIF4E in the nucleus: taking the road less traveled

Targeting the N Terminus of Eif4ai for Inhibition of Its Catalytic Recycling.

Targeting Transcription Factor SALL4 in Acute Myeloid Leukemia by Interrupting Its Interaction with an Epigenetic Complex.

Eukaryotic translation initiation factors and cancer.